News and Trends 14 Oct 2022Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals This week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas Turner, CEO and co-founder of Cultivated Biosciences; and Joanna Magaji, conference manager for the BiotechX event. BiotechX event taking place in Basel in November BiotechX, […] October 14, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has invested in Samsara Therapeutics Inc. Samsara Therapeutics is a biotech company focusing on discovering and developing therapeutics to restore autophagy – the process by which cells recycle damaged or dysfunctional components. Samsara is developing several novel, […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Amphista Therapeutics and Domainex Ltd partner for integrated drug services Amphista Therapeutics Ltd., has selected Domainex Ltd as one of its trusted partners to provide integrated drug discovery services to support its research programs. The partnership will also advance its portfolio of drug discovery projects targeting protein degradation (TPD). Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to deal with disease-causing […] October 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Novavax COVID-19 vaccine data supports homologous and heterologous boosting Data in from adults and adolescents aged 12-17 collected in a phase 3 trial of a prototype Novavax COVID-19 vaccine showed it had achieved its pre-specified immunologic endpoint. Study 307 met its primary endpoint, showing three lots of the vaccine tested as a heterologous booster induced consistent immune responses in previously vaccinated adults aged 18-49. […] October 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders SiSaf Ltd, an RNA delivery and therapeutics company, is initiating the U.S. FDA Regulatory process to obtain orphan drug designation for SIS-101-ADO. SIS-101-ADO is a siRNA therapeutic for patients with autosomal dominant osteopetrosis type 2 (ADO2), a rare genetic skeletal disorder. The request for orphan drug designation and advancement through the regulatory process that SIS-101-ADO […] October 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Virtual trials growth leads to Cambridge Cognition acquiring eClinicalHealth Cambridge Cognition is looking to accelerate its growth through the acquisition of eClinicalHealth Ltd (eCH). Cambridge Cognition is an active player in the central nervous system (CNS) market, supplying digital solutions to assess brain health. eCH is a full-service digital technology provider working on virtual clinical trials for three of the world’s top 10 largest […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Emergex looks to microneedle patches with Zosano Pharma acquisition Emergex Vaccines Holding Limited has acquired the assets of California-based company Zosano Pharma Corporation. Emergex is a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines. The assets acquired include intellectual property, license agreements, and manufacturing equipment. They also include Zosano’s proprietary microneedle array […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Oct 2022 Needle-free diabetes care: 7 devices that painlessly monitor blood sugar Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be […] October 7, 2022 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 6 Oct 2022 15 biotech companies shaking up the scene in Cambridge Cambridge has a large biotech scene that is starting to rival that of its U.S. namesake. Here are 15 biotech companies in Cambridge you should know about. The U.K. is home to several biotech hubs, including the golden triangle of London, Oxford and Cambridge, as well as Bristol and Stevenage. Cambridge is a small but […] October 6, 2022 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Novartis Biome UK Heart Health Catalyst 2022 winners announced Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. Lifelight and PocDoc will receive support to scale their innovative digital […] October 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data. Under the terms of the agreement, Genmab will be responsible for the […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email